The effect of rebamipide for the protection of the oral mucositis in the breast cancer patients

The effect of rebamipide for the protection of the oral mucositis in the breast cancer patients - Cinderella-01

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009507

Enrollment

160

Registered

2012-12-09

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bresat cancer

Interventions

rebamipide

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. early breast cancer 2. planned FEC or TC chemotherapy on the neo or post-operation adjuvant chemotherapy 3. no treatment for BC 4. normal organ function 5. writtten IC

Exclusion criteria

Exclusion criteria: 1. difficult in the oral administration 2. metastatic of reccurent Brast cancer

Design outcomes

Primary

Measure	Time frame
rate of the oral mucositis over grade 1	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026